The 340B debate can't ignore supply chain realities
Healthcare distributors deliver roughly 15 million medicines and healthcare products every day to hospitals, physicians’ offices, pharmacies, and other providers across the country. While they play a critical role in keeping the healthcare supply chain moving, they are largely removed from the design and operation of the 340B Drug Pricing Program. As lawmakers debate changes to 340B, it is essential to recognize the distinct role distributors serve — and avoid policies that assign them responsibility for decisions they do not control.
TL;DR
- Healthcare distributors deliver approximately 15 million medicines daily.
- Distributors play a critical role in the healthcare supply chain but are largely removed from the design and operation of the 340B Drug Pricing Program.
- The 340B program was created to help safety-net providers stretch resources, but concerns exist that it now benefits richer providers more than poorer patients.
- Distributors do not set 340B prices, determine eligibility, or decide how savings are used; these decisions rest with manufacturers and covered entities.
- Some state proposals incorrectly merge the distinct roles of manufacturers, distributors, and covered entities regarding access to 340B drugs.
- Distributors have federal obligations to monitor and report suspicious orders, which could conflict with state laws prohibiting any 'delay' or 'restriction' on drug access.
- Clear role clarity is essential, distinguishing between entities that shape program terms and those that implement logistics.
- Productive policy discussions require precision about who controls what within the 340B framework.